Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators

[1]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[2]  John M.S. Bartlett,et al.  Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? , 2005, Clinical Cancer Research.

[3]  R. Salgia,et al.  Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. , 2005, Cancer research.

[4]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[5]  R. Schiff,et al.  Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Castro.  ATAC trial update , 2005, The Lancet.

[7]  J. Robertson,et al.  Endocrine treatment options for advanced breast cancer--the role of fulvestrant. , 2005, European journal of cancer.

[8]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[9]  K. Blackwell,et al.  The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. , 2005, Cancer research.

[10]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[12]  Heidi L. Weiss,et al.  Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer , 2004, Clinical Cancer Research.

[13]  J. Qin,et al.  Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. , 2004, Molecular cell.

[14]  W. Sellers,et al.  High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. , 2004, Cancer cell.

[15]  X. Guan,et al.  Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer , 2004, Clinical Cancer Research.

[16]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[18]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[19]  R. Carlson.  Sequencing of Endocrine Therapies in Breast Cancer – Integration of Recent Data , 2002, Breast Cancer Research and Treatment.

[20]  J. Pasqualini.  Breast cancer: Prognosis, Treatment and Prevention Published in July 2002 by Marcel Dekker Inc., New York, USA; Basel, Switzerland; 656 pages; ISBN: 0-8247-0712-5; US$ 165.00 , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  Baljit Singh,et al.  Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue , 2001, Breast Cancer Research and Treatment.

[22]  M. Dowsett,et al.  Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial , 2003 .

[23]  S. Jiang,et al.  Estrogen receptor corepressors -- a role in human breast cancer? , 2003, Endocrine-related cancer.

[24]  Rakesh Kumar,et al.  Emerging roles of MTA family members in human cancers. , 2003, Seminars in oncology.

[25]  A. Buzdar,et al.  The current status of aromatase inhibitors in the management of breast cancer. , 2003, The Surgical clinics of North America.

[26]  R. Vadlamudi,et al.  Functional Interactions between the Estrogen Receptor Coactivator PELP1/MNAR and Retinoblastoma Protein* , 2003, Journal of Biological Chemistry.

[27]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Rosenzweig,et al.  Hormonal therapy for breast cancer: focus on fulvestrant. , 2003, Clinical journal of oncology nursing.

[29]  A. Wellstein,et al.  Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathway , 2003, Oncogene.

[30]  Lei Li,et al.  Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Ping Zhang,et al.  Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. , 2003, Molecular endocrinology.

[32]  C. Hudis,et al.  Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[34]  P. Blackmore,et al.  Membrane receptors for steroid hormones: Signal transduction and physiological significance , 2003, Journal of cellular biochemistry.

[35]  E. Levin,et al.  Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.

[36]  Gottfried Konecny,et al.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.

[37]  G. Figtree,et al.  Truncated Estrogen Receptor &agr; 46-kDa Isoform in Human Endothelial Cells: Relationship to Acute Activation of Nitric Oxide Synthase , 2003, Circulation.

[38]  A. Wellstein,et al.  Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. , 2003, Oncogene.

[39]  A. Parfitt,et al.  Reversal of bone loss in mice by nongenotropic signaling of sex steroids. , 2003, Science.

[40]  A. Bilancio,et al.  Sex steroid hormones act as growth factors , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  A. Wakeling,et al.  Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy. , 2002, Endocrine-related cancer.

[42]  A. Lipton,et al.  Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. , 2002, Oncology reports.

[43]  Chi-Wai Wong,et al.  Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Chris P. Miller,et al.  SERMs: evolutionary chemistry, revolutionary biology. , 2002, Current pharmaceutical design.

[45]  C. J. Barnes,et al.  A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.

[46]  R. Schiff,et al.  The Importance of the Estrogen Receptor in Breast Cancer , 2002 .

[47]  A. Cato,et al.  Rapid Actions of Steroid Receptors in Cellular Signaling Pathways , 2002, Science's STKE.

[48]  V. Speirs.  Oestrogen receptor β in breast cancer: good, bad or still too early to tell? , 2002 .

[49]  R. Nicholson,et al.  Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer , 2002, Annals of the New York Academy of Sciences.

[50]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase , 2002, Molecular and Cellular Biology.

[51]  E. Levin.  Cellular functions of plasma membrane estrogen receptors , 2002, Steroids.

[52]  John H. White,et al.  Diversity in the mechanisms of gene regulation by estrogen receptors. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[53]  E. Filardo,et al.  Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[54]  R. McPherson,et al.  The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[55]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[56]  Chi-Hung Lin,et al.  Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer , 2002, International journal of cancer.

[57]  C. J. Barnes,et al.  A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. , 2002, Nature.

[58]  E. Winer,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  V. Speirs.  Oestrogen receptor beta in breast cancer: good, bad or still too early to tell? , 2002, The Journal of pathology.

[60]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. , 2002, Molecular and cellular biology.

[61]  R. McPherson,et al.  Linkage of Rapid Estrogen Action to MAPK Activation by ER-Shc Association and Shc Pathway Activation , 2001 .

[62]  M. Dowsett,et al.  HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. , 2001, Cancer research.

[63]  Adrian V. Lee,et al.  Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  A. Sahin,et al.  Molecular Cloning and Characterization of PELP1, a Novel Human Coregulator of Estrogen Receptor α , 2001 .

[65]  E. Levin.  highlighted topics Genome and Hormones: Gender Differences in Physiology Invited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors , 2001 .

[66]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J E Paciga,et al.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.

[68]  C. Klinge.  Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.

[69]  C. Turck,et al.  Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity* , 2001, The Journal of Biological Chemistry.

[70]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[71]  R. Kumar,et al.  Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. , 2001, The Journal of biological chemistry.

[72]  R. Mass.  The role of HER-2 expression in predicting response to therapy in breast cancer. , 2000, Seminars in oncology.

[73]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[74]  L. Murphy,et al.  Altered expression of estrogen receptor coregulators during human breast tumorigenesis. , 2000, Cancer research.

[75]  G. Figtree,et al.  Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.

[76]  A. Lenferink,et al.  Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.

[77]  C K Osborne,et al.  Selective estrogen receptor modulators: structure, function, and clinical use. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Privalsky,et al.  The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.

[79]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[80]  M. van Eickels,et al.  Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway* , 2000, The Journal of Biological Chemistry.

[81]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .

[82]  J. Robertson,et al.  Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.

[83]  M. Garabedian,et al.  Potentiation of Human Estrogen Receptor α Transcriptional Activation through Phosphorylation of Serines 104 and 106 by the Cyclin A-CDK2 Complex* , 1999, The Journal of Biological Chemistry.

[84]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[85]  K. Horwitz,et al.  Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[86]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[87]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[88]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[89]  B. Katzenellenbogen,et al.  Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.

[90]  J. Blenis,et al.  pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167 , 1998, Molecular and Cellular Biology.

[91]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[92]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[93]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[94]  B. Katzenellenbogen,et al.  Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation* , 1996, The Journal of Biological Chemistry.

[95]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[97]  B. Katzenellenbogen,et al.  Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. , 1994, The Journal of biological chemistry.

[98]  B. O’Malley,et al.  Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[99]  B. Katzenellenbogen,et al.  Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. , 1993, Molecular endocrinology.

[100]  P. Chambon,et al.  Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region. , 1993, The EMBO journal.

[101]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  M. Parker.  Nuclear hormone receptors : molecular mechanisms, cellular functions, clinical abnormalities , 1991 .

[103]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[104]  P. Chambon,et al.  Cloning of the human oestrogen receptor cDNA. , 1986, Journal of steroid biochemistry.

[105]  W. McGuire,et al.  Multiple progesterone receptor assays in human breast cancer. , 1984, Cancer research.

[106]  A. Lacassagne,et al.  Hormonal Pathogenesis of Adenocarcinoma of the Breast , 1936 .

[107]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.